MX2023003054A - Formas solidas de un inhibidor de cdk4. - Google Patents
Formas solidas de un inhibidor de cdk4.Info
- Publication number
- MX2023003054A MX2023003054A MX2023003054A MX2023003054A MX2023003054A MX 2023003054 A MX2023003054 A MX 2023003054A MX 2023003054 A MX2023003054 A MX 2023003054A MX 2023003054 A MX2023003054 A MX 2023003054A MX 2023003054 A MX2023003054 A MX 2023003054A
- Authority
- MX
- Mexico
- Prior art keywords
- solid forms
- cdk4 inhibitor
- pharmaceutical compositions
- forms
- cdk4
- Prior art date
Links
- 239000007787 solid Substances 0.000 title abstract 3
- 229940083347 Cyclin-dependent kinase 4 inhibitor Drugs 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Fats And Perfumes (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Esta invención se refiere a formas cristalinas y amorfas de 1,5-anhidro-3-({5-cloro-4-[4-fluoro-2-(2-hidroxipropan-2-il)-1-(p ropan-2-il)-1H-benzimidazol-6-il]pirimidin-2-il}amino)-2,3-dideox i-D-treo-pentitol, a composiciones farmacéuticas que comprende dichas formas sólidas, y al uso de dichas formas sólidas y composiciones farmacéuticas para el tratamiento del cáncer.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063078636P | 2020-09-15 | 2020-09-15 | |
| US202163240268P | 2021-09-02 | 2021-09-02 | |
| PCT/IB2021/058320 WO2022058871A1 (en) | 2020-09-15 | 2021-09-13 | Solid forms of a cdk4 inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023003054A true MX2023003054A (es) | 2023-04-05 |
Family
ID=78000744
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023003054A MX2023003054A (es) | 2020-09-15 | 2021-09-13 | Formas solidas de un inhibidor de cdk4. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230357211A1 (es) |
| EP (1) | EP4214202A1 (es) |
| JP (2) | JP7260606B2 (es) |
| KR (1) | KR20230069983A (es) |
| AU (1) | AU2021345531B2 (es) |
| BR (1) | BR112023004713A2 (es) |
| CA (1) | CA3195063A1 (es) |
| MX (1) | MX2023003054A (es) |
| TW (2) | TWI809503B (es) |
| WO (1) | WO2022058871A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023100070A1 (en) * | 2021-12-02 | 2023-06-08 | Pfizer Inc. | Cdk4 inhibitor for the treatment of cancer |
| WO2024023703A1 (en) | 2022-07-29 | 2024-02-01 | Pfizer Inc. | Dosing regimens comprising a kat6 inhibitor for the treatment of cancer |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
| WO2000035296A1 (en) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Improved release of medicament active agents from a chewing gum coating |
| CR20190062A (es) | 2016-08-15 | 2019-05-22 | Pfizer | Inhibidores de cdk2/4/6 |
| KR102661053B1 (ko) * | 2018-04-26 | 2024-04-26 | 화이자 인코포레이티드 | 사이클린 의존성 키나제 억제제로서 2-아미노-피리딘 또는 2-아미노-피리미딘 유도체 |
-
2021
- 2021-09-13 US US18/245,039 patent/US20230357211A1/en active Pending
- 2021-09-13 WO PCT/IB2021/058320 patent/WO2022058871A1/en active Application Filing
- 2021-09-13 KR KR1020237012766A patent/KR20230069983A/ko unknown
- 2021-09-13 MX MX2023003054A patent/MX2023003054A/es unknown
- 2021-09-13 BR BR112023004713A patent/BR112023004713A2/pt unknown
- 2021-09-13 AU AU2021345531A patent/AU2021345531B2/en active Active
- 2021-09-13 CA CA3195063A patent/CA3195063A1/en active Pending
- 2021-09-13 EP EP21783049.6A patent/EP4214202A1/en active Pending
- 2021-09-13 JP JP2021148619A patent/JP7260606B2/ja active Active
- 2021-09-14 TW TW110134168A patent/TWI809503B/zh active
- 2021-09-14 TW TW112102545A patent/TW202334125A/zh unknown
-
2022
- 2022-10-27 JP JP2022172594A patent/JP7291839B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA3195063A1 (en) | 2022-03-24 |
| BR112023004713A2 (pt) | 2023-04-18 |
| JP2022186995A (ja) | 2022-12-15 |
| KR20230069983A (ko) | 2023-05-19 |
| AU2021345531A1 (en) | 2023-04-20 |
| US20230357211A1 (en) | 2023-11-09 |
| TW202216698A (zh) | 2022-05-01 |
| TW202334125A (zh) | 2023-09-01 |
| JP7260606B2 (ja) | 2023-04-18 |
| WO2022058871A1 (en) | 2022-03-24 |
| JP2022049005A (ja) | 2022-03-28 |
| EP4214202A1 (en) | 2023-07-26 |
| TWI809503B (zh) | 2023-07-21 |
| JP7291839B2 (ja) | 2023-06-15 |
| AU2021345531B2 (en) | 2024-02-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023003054A (es) | Formas solidas de un inhibidor de cdk4. | |
| CY1123625T1 (el) | Συνθεσεις και μεθοδοι για θεραπεια διαταραχων χρησης αλκοολης, πονου και αλλων ασθενειων | |
| UA100846C2 (uk) | Сполуки та композиція як інгібітори протеїнкінази | |
| MY138252A (en) | Azabicyclic-substitud fused-heteroaryl compounds for the treatment of disease | |
| WO2003105771A3 (en) | 1 - ((5-ARYL-1,2,4-OXADIAZOL-3-YL) BENZYL) AZETIDINE-3-CARBOXYLATES AND 1 - ((5-ARYL-1,2,4-OXADIAZOL-3-YL) BENZYL) PYRROLIDINE-3-CARBOXYLATES FOR USE AS EDG RECEPTOR AGONISTS | |
| MX2009006081A (es) | Compuestos y composiciones como inhibidores de cinasa de proteina. | |
| DK1480961T3 (da) | Glutaminylbaserede DPIV-inhibitorer | |
| MX2009005881A (es) | Derivados de 2-(piperidin-4-il)-4-fenoxi o fenilamino-pirimidina como inhibidores de la transcriptasa inversa no nucleosida. | |
| EP1841426A4 (en) | TERTIARY CARBINAMINES INCLUDING SUBSTITUTED HETEROCYCLES AS BETA SECRETASE INHIBITORS AND FOR THE TREATMENT OF ALZHEIMER'S DISEASE | |
| MX2009009920A (es) | Inhibidores no nucleosidos de transcriptasa inversa. | |
| TNSN08139A1 (fr) | Composes therapeutiques | |
| IL176546A0 (en) | Imidazoline derivatives having cb1-antagonistic activity | |
| MX2020001531A (es) | Nuevos compuestos hetorociclicos como inhibidores de cdk8/19. | |
| MX2009007669A (es) | 1,3,-dioxanos sustituidos y sus usos. | |
| RS50578B (sr) | Supstituisani 2-aminotetralini za preventivni tretman parkinsonove bolesti | |
| UA98928C2 (ru) | 1,4-дигидропиридинконденсированные гетероциклы, способ их получения, применения и композиция, которая содержит их | |
| PE20081169A1 (es) | Compuestos tipo pirazol y triazol sustituidos como inhibidores de ksp | |
| ATE403426T1 (de) | Opioid-rezeptor-aktive 4-(3-hydroxyphenyl) oder 4-(3-alkoxyphenyl)-1,2,4-triazol-verbindungen | |
| MX2020013811A (es) | Compuestos. | |
| MX2009010932A (es) | Inhibidores no nucleosidos de transcriptasa inversa. | |
| MX2021001335A (es) | Inhibidores de ckd8/19. | |
| BRPI0411293A (pt) | composto, composição farmacêutica, processo para a preparação de um composto, e, uso de um composto | |
| BRPI0415022A (pt) | sais e polimorfos de um composto de indolinona substituìda com pirrol | |
| WO2024028458A3 (en) | Crystalline forms and salts of a muscarinic receptor agonist | |
| MX2020003045A (es) | Inhibidor de mpges-1 para el tratamiento de dolor de osteoartritis. |